

APSA Manuscript Submission Open through March 15, 2022

Authors presenting abstracts in Plenary, Scientific and Committee Breakout sessions are encouraged to submit manuscripts for publication in the *Journal of Pediatric Surgery (JPS)*. Manuscript submission is optional and not required for abstract presentation*. Videos and posters are **not eligible unless** they have been identified as candidates for the Quality Award.

*If your abstract was specifically identified as a candidate for the Quality Award: 1) manuscript submission is mandatory; 2) if you choose not to publish your work in the JPS, submit your manuscript directly to the Quality and Safety Committee as instructed in an earlier email, do not submit your manuscript via the APSA platform.

Selected manuscripts will be published in the January 2023 Issue of the *Journal of Pediatric Surgery*

Submission Instructions

Submissions that do not adhere to the instructions will not be considered for publication.

- The manuscript is submitted as two MS Word files: title page is one, separate file; text and tables/graphics/pictures are combined in the second file.
- 2. The submission is required to be original work and not published previously.
- 3. Files must be in MS Word format and may not exceed 3MB.
- 4. **Text, excluding the title page, must be de-identified to authors and institution**. The review process for the publications committee is blind.
- 5. Manuscripts must be double-spaced and are limited to 12 pages. Page limit does **not** include title page, legend, tables, figures, illustrations and reference pages.
- 6. Title Page must include the following:
 - o Title
 - o Authors' first and last names
 - o Institutions represented
 - o Name, mailing address, telephone and e-mail address of the corresponding author
 - Author contributions in one or more of the following categories (ghost-writing is not acceptable and contributors who do not meet the following criteria should be listed in the acknowledgement):
 - o study conception and design
 - acquisition of data
 - analysis and interpretation of data
 - drafting of manuscript
 - critical revision of manuscript
 - Annotations of changes that should be included in the final manuscript that contain identifying information regarding the authors or the institution

- 7. Manuscript information should be displayed in the following order:
 - o Title
 - Level of Evidence (for clinical studies, see below)
 - Type of study
 - Abstract 300 words: Background/purpose, Methods, Results and Conclusions
 - Keywords up to 6 (index words no longer used)
 - Body of manuscript
 - Legend sheet for figures. Figures are labeled according to the legend sheet.
 - References
 - Tables and Figures
- 8. Tables and figures should be cited in order with their position marked in the margin of the manuscript.
- 8. References must be double-spaced, numbered and compiled according to citation order in the text, in the *Journal of Pediatric Surgery*/Vancouver format.
- 10. For clinical research studies, authors are encouraged to follow the JPS Clinical Research Guidelines, posted on the <u>APSA website</u> for your convenience.

IMPORTANT! Did Your Remember to Review and De-identify your Manuscript? In addition to submitting your title page as a separate file, to ensure a blind review process, we recommend you review your manuscript thoroughly and remove any mention of the institution or identifying information regarding the institution or the authors. This includes mention of prior publications by your group, and reference to the institution specific IRB (see sample manuscript for details). This information will be entered in later revisions if the paper is accepted.

IF YOUR MANUSCRIPT CONTAINS IDENTIFYING INFORMATION REGARDING THE AUTHORS OR THE INSTITUTION IT WILL NOT BE REVIEWED.

Questions? Contact APSA

Journal of Pediatric Surgery

Levels of Evidence: Although this will be reviewed by our Editorial Staff, and their opinion will be final, the Journal asks authors to assign a Level of Evidence to all clinically oriented manuscripts. The following table is offered to assist authors:

LEVEL IRandomized controlled trials with adequate statistical power to detect differences (narrow confidence intervals) and follow-up >80%High-quality prospective cohort study with >80% criteria in a study with >80% criteria in a study with values obtained from many studies, study used universally applied seaseReasonable costs a alternatives used in study with values obtained from many studies, study used universally applied global standardLEVEL IILower-quality randomized trials (follow-up <80%,	Type of	Treatment Study	Prognosis Study	Study of Diagnostic Test	Cost Effectiveness
trials with adequate statistical power to detect differences (narrow confidence intervals) and follow-up >80% LEVEL II Lower-quality randomized trials (follow-up <80%, trials with adequate study with >80% criteria in a study with values obtained from many studies, study used universally applied giagnostic gold" standard analyses Level II Lower-quality prospective cohort (follow-up <80%, study (<80% follow-up, and all patients and a universally applied giagnostic gold" standard analyses Reasonable costs a alternatives used in study with values obtained from many studies, study used universally applied gold" standard analyses Reasonable costs a alternatives used in study with values obtained from many studies, study used gold" standard analyses Lower-quality prospective cohort diagnostic criteria in a study with values obtained from many studies, study used gold" standard analyses	Study	Decile de la controlle d	LP-L Pt		Study
statistical power to detect differences (narrow confidence intervals) and follow-up >80% disease LEVEL II Study with >80% criteria in a consecutive series of patients enrolled at same time point in disease Lower-quality randomized trials (follow-up <80%, study with values obtained from many studies, study used universally applied gisease "gold" standard analyses Reasonable costs a alternatives used in study with values obtained from many studies, study used universally applied gisease "gold" standard analyses Reasonable costs and a universally applied gisease analyses Consecutive series of patients and a universally applied gisease analyses Study with values obtained from many studies, study used universally applied gisease analyses Consecutive series of study with values obtained from many studies, study used universally applied gisease analyses	LEVELI				
detect differences (narrow confidence intervals) and follow-up >80% LEVEL II Lower-quality randomized trials (follow-up <80%, follow-up <80% follow-up, and all patients enrolled at same time point in disease follow-up, and all patients enrolled at same time point in disease follow-up, and all patients and a universally applied universally applied grandard follow-up analyses Level II Lower-quality prospective cohort (follow-up <80%, study (<80% follow-up, and all patients enrolled at universally applied grandard follow-up analyses Reasonable costs and a universally applied grandard follow-up analyses Consecutive series of patients and a universally applied grandard follow-up analyses Reasonable costs and a universally applied grandard follow-up analyses					
(narrow confidence intervals) and follow-up >80% LEVEL II Lower-quality randomized trials (follow-up <80%, study (<80% follow-up, and follow-up) patients enrolled at same time point in disease universally applied universally applied generally gold" standard analyses patients and a universally applied generally analyses Development of diagnostic criteria in a study exercise of study used multi-way sensitivity analyses Reasonable costs and a universally applied generally analyses Reasonable costs and a universally applied generally analyses Reasonable costs and a universally applied generally analyses					
intervals) and follow-up same time point in disease "gold" standard analyses LEVEL II Lower-quality randomized trials (follow-up <80%, study (<80% follow-up, consecutive series of study with values time point in disease "gold" standard analyses Development of diagnostic criteria in a consecutive series of study with values					
Secondary Seco				•	
LEVEL II Lower-quality randomized trials (follow-up <80%, follow-up, a total consecutive series of consecutive			-	,	
randomized trials prospective cohort diagnostic criteria in a laternatives used in study (<80% follow-up, consecutive series of study with values	1 5/51 11				
(follow-up <80%, study (<80% follow-up, consecutive series of study with values	LEVELII			•	
l incorporar representantiana l motionata correlladata l motionata con da la labacidad francisco lincita					
					obtained from limited
techniques, no different time points in universally applied studies, study uses					
		masking)	disease)	gold Standard	multi-way sensitivity
Dragnostive Potropostive study		Dragnative	Potroppostive study		analyses
Prospective Retrospective study			Retrospective study		
comparative study Untreated controls		Comparative Study	Untrooted controls		
from a randomized					
controlled trial					
	I EVEL III	Casa-control study		Study of	Analyses based on a
nonconsecutive limited section of		Case-control study	Case-control study	1	
		Petrospective			alternatives and costs,
		•			or poor estimates of
"gold" standard costs		Comparative Study			· ·
	I EVEL IV	Case series with no	Case series with no		No sensitivity analysis
comparison group comparison group reference standard					
Companson group Companson group Telefence standard				Totolerice standard	
Case control study				Case control study	
LEVEL V Expert opinion Expert opinion Expert opinion Expert opinion	I EVEL V	Expert opinion	Expert opinion	·	Expert opinion